Wave Life Sciences Ltd. Stock

Equities

WVE

SG9999014716

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-06-21 EDT 5-day change 1st Jan Change
5.25 USD +1.74% Intraday chart for Wave Life Sciences Ltd. -15.73% +3.96%
Sales 2024 * 67.81M 92.85M Sales 2025 * 50.93M 69.73M Capitalization 643M 880M
Net income 2024 * -119M -163M Net income 2025 * -139M -190M EV / Sales 2024 * 7.03 x
Net cash position 2024 * 166M 228M Net cash position 2025 * 113M 154M EV / Sales 2025 * 10.4 x
P/E ratio 2024 *
-5.94 x
P/E ratio 2025 *
-5.56 x
Employees 267
Yield 2024 *
-
Yield 2025 *
-
Free-Float 81.82%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.74%
1 week-15.73%
Current month-15.05%
1 month-16.93%
3 months-12.50%
6 months+4.37%
Current year+3.96%
More quotes
1 week
5.13
Extreme 5.13
6.34
1 month
5.13
Extreme 5.13
6.51
Current year
3.50
Extreme 3.5
7.67
1 year
3.45
Extreme 3.45
7.67
3 years
1.16
Extreme 1.16
7.67
5 years
1.16
Extreme 1.16
39.98
10 years
1.16
Extreme 1.16
56.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 13-11-30
Director of Finance/CFO 54 14-06-30
Chief Tech/Sci/R&D Officer 63 14-07-31
Members of the board TitleAgeSince
Chairman 56 16-11-09
Director/Board Member 66 19-09-03
Director/Board Member 52 17-01-31
More insiders
Date Price Change Volume
24-06-21 5.25 +1.74% 1,373,797
24-06-20 5.16 -9.63% 458,088
24-06-18 5.71 -4.67% 380,023
24-06-17 5.99 -3.85% 504,912
24-06-14 6.23 -3.86% 369,717

Delayed Quote Nasdaq, June 21, 2024 at 04:00 pm

More quotes
Wave Life Sciences Ltd. is a biotechnology company. The Company is focused on unlocking the potential of RNA medicines (oligonucleotides), or those targeting ribonucleic acid (RNA), to transform human health. Its RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing and RNA interference (RNAi), providing Company with capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. These programs include WVE-N531, WVE-006 and WVE-003. It is also building a pipeline of novel A-to-I RNA editing oligonucleotides (AIMers).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
5.25 USD
Average target price
12.86 USD
Spread / Average Target
+144.90%
Consensus